Literature DB >> 12034028

Enhanced tumor development in mice lacking a functional type I interferon receptor.

Sandrine Picaud1, Boris Bardot, Edward De Maeyer, Isabelle Seif.   

Abstract

The aim of this study was to investigate the contribution of endogenous - that is, without the addition of any interferon (IFN) inducer - type I IFN production in the defense against tumor development. To this purpose, the IFN-alpha receptor (IFNAR) knockout (KO)-induced mutation, resulting in the complete absence of IFN-alpha/beta activity, was introduced into a C3H genetic background by 10 backcross generations, followed by brother-sister matings for at least four generations. The resulting mice were inoculated either with syngeneic C3H melanoma K1735 cells, with allogeneic 3LL carcinoma cells, or with allogeneic B16F10 melanoma cells. With all three tumor cell lines, tumor development and ensuing mortality were enhanced in the IFNAR KO animals. This indicates that endogenous IFN-alpha/beta production is a mediator of natural immunity to tumor development.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12034028     DOI: 10.1089/10799900252952244

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  17 in total

1.  Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.

Authors:  Raj Deonarain; Amit Verma; Andrew C G Porter; Dirk R Gewert; Leonidas C Platanias; Eleanor N Fish
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

2.  Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.

Authors:  Arnold I Chin; Andrea K Miyahira; Anthony Covarrubias; Juli Teague; Beichu Guo; Paul W Dempsey; Genhong Cheng
Journal:  Cancer Res       Date:  2010-03-16       Impact factor: 12.701

Review 3.  The molecular basis for differential type I interferon signaling.

Authors:  Gideon Schreiber
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

4.  Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.

Authors:  Joanne Y H Lim; Scott A Gerber; Shawn P Murphy; Edith M Lord
Journal:  Cancer Immunol Immunother       Date:  2013-12-20       Impact factor: 6.968

5.  Interferon-Stimulated Genes Are Transcriptionally Repressed by PR in Breast Cancer.

Authors:  Katherine R Walter; Merit L Goodman; Hari Singhal; Jade A Hall; Tianbao Li; Sean M Holloran; Gloria M Trinca; Katelin A Gibson; Victor X Jin; Geoffrey L Greene; Christy R Hagan
Journal:  Mol Cancer Res       Date:  2017-07-06       Impact factor: 5.852

6.  The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity.

Authors:  Byron C Burnette; Hua Liang; Youjin Lee; Lukasz Chlewicki; Nikolai N Khodarev; Ralph R Weichselbaum; Yang-Xin Fu; Sogyong L Auh
Journal:  Cancer Res       Date:  2011-02-07       Impact factor: 12.701

Review 7.  Immunotherapy of cancer: from vision to standard clinical practice.

Authors:  Christoph H Huber; Thomas Wölfel
Journal:  J Cancer Res Clin Oncol       Date:  2004-07       Impact factor: 4.553

8.  Host STAT2/type I interferon axis controls tumor growth.

Authors:  Chanyu Yue; Jun Xu; Marc Daryl Tan Estioko; Kevin P Kotredes; Yolanda Lopez-Otalora; Brendan A Hilliard; Darren P Baker; Stefania Gallucci; Ana M Gamero
Journal:  Int J Cancer       Date:  2014-06-17       Impact factor: 7.396

Review 9.  Hope and fear for interferon: the receptor-centric outlook on the future of interferon therapy.

Authors:  Serge Y Fuchs
Journal:  J Interferon Cytokine Res       Date:  2013-04       Impact factor: 2.607

10.  Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses.

Authors:  Qunfang Li; Michael A Tainsky
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.